Taurine 11 pp 87-99 | Cite as

Taurine Improves the Actions of Metformin and Lovastatin on Plasma Markers of Carbohydrate and Lipid Dysfunction of Diabetic Rats

  • Kashyap Pandya
  • Cesar A. Lau-Cam
Conference paper
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1155)


The present study has investigated the effect of adding taurine (TAU) to a treatment of diabetes with metformin (MET), a hypoglycemic, and lovastatin (LOV), an antihyperlipidemic. To this end, male Sprague-Dawley rats, agent, 250–275 g in weight, were made diabetic with a single 60 mg/kg intraperitoneal (i.p.) dose of streptozocin (STZ) in 10 mM citrate buffer pH 4.5, and, after 14 days, treated daily with oral doses of MET (2.4 mM/kg), LOV (0.075 mM/kg) or TAU (2.4 mM/kg), and with binary and ternary combinations of these agents. Rats receiving only 10 mM citrate buffer pH 4.5 or only STZ served as negative and positive controls, respectively. In addition, rats receiving insulin (INS, 4 units/kg) by the subcutaneous route served as a reference treatment. All the rats were sacrificed on day 57 and their bloods collected into heparinized tubes. The corresponding plasma samples were analyzed for their glucose (GLC), insulin (INS), glycated hemoglobin (HbA1c), cholesterol (CHOL) and triglycerides (TG) contents. In comparison to normal rats, diabetic ones showed marked increases in GLC (+313%), HbA1c (+207%), CHOL (+66%) and TG (+188) and a profound decrease of INS levels (−76%) (p < 0.001 vs. control values). Among the various treatments, one with INS produced the greatest lowering effect on the plasm a GLC (+23%, p < 0.05), INS (+23%, p < 0.05) and TG (+3%), with the remaining changes being similar to those seen with MET. A treatment with MET reduced all the diabetic changes by at least threefold; and one with LOV had a significant (p < 0.001) lowering effect on the plasma CHOL and TG but was without an effect on the plasma GLC, INS and HbA1c. In common with LOV, TAU reduced the diabetic levels of both CHOL and TG and, in addition, reduced the diabetic plasma GLC and raised the corresponding INS level. Among binary combinations, one with LOV-MET provided a greater effect than MET alone only in terms of the plasma CHOL and TG; and one with LOV-TAU was only significantly better than TAU alone in lowering the TG levels. However, a treatment with LOV-MET-TAU led to reductions in all the plasma parameters examined that were much greater than those achieved with any of the individual agents or with their binary combinations (at p ≤ 0.05).


Diabetes Rats Streptozotocin Metabolic changes Metformin Lovastatin Taurine 





Diabetes mellitus




Glycated hemoglobin














  1. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20:470–475PubMedGoogle Scholar
  2. Alvarado-Vásquez N, Zamudio P, Cerón E, Vanda B, Zenteno E, Carvajal- Sandoval G (2003) Effect of glycine in streptozotocin-induced diabetic rats. Comp Biochem Physiol Part C Toxicol Pharmacol 134:521–527CrossRefGoogle Scholar
  3. Bailey CJ, Mynett KJ, Page T (1994) Importance of the intestine as a site of metformin-stimulated glucose utilization. Br J Pharmacol 112:671–675CrossRefGoogle Scholar
  4. Brøns C, Spohr C, Storgaard H, Dyerberg J, Vaag A (2004) Effect of taurine treatment on insulin secretion and action, and on serum lipid levels in overweight men with a genetic predisposition for type II diabetes mellitus. Eur J Clin Nutr 58:1239–1247CrossRefGoogle Scholar
  5. Brownlee M, Cerami A (1981) The biochemistry of the complications of diabetes mellitus. Annu Rev Biochem 50:385–432CrossRefGoogle Scholar
  6. Carlsen SM, Rossvoll O, Bjerve KS, Folling I (1996) Metformin improves blood lipid pattern in nondiabetic patients with coronary heart disease. J Intern Med 239:227–233CrossRefGoogle Scholar
  7. Carneiro EM, Latorraca MQ, Araujo E, Beltrá M, Oliveras MJ, Navarro M, Berná G, Bedoya FJ, Velloso LA, Soria B, Martín F (2009) Taurine supplementation modulates glucose homeostasis and islet function. J Nutr Biochem 20:503–511. 2009CrossRefGoogle Scholar
  8. Chogtu B, Magazine R, Bairy KL (2015) Statin use and risk of diabetes mellitus. World J Diabetes 6:352–357CrossRefGoogle Scholar
  9. Garg A, Grundy SM (1988) Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med 318:81–86CrossRefGoogle Scholar
  10. Guo J, Gao Y, Cao X, Zhang J, Chen W (2017) Cholesterol-lowering effect of taurine in HepG2 cell. Lipids Health Dis 16:56CrossRefGoogle Scholar
  11. Hother-Nielsen O, Schmitz O, Andsersen PH, Beck-Nielsen H, Pedersen O (1989) Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes. Acta Endocrinol (Copenh) 120:257–265CrossRefGoogle Scholar
  12. Ito T, Schaffer SW, Azuma J (2012) The potential usefulness of taurine on diabetes mellitus and its complications. Amino Acids 42:1529–1539CrossRefGoogle Scholar
  13. Kim KS, Oh DH, Kim JY, Lee BG, You JS, Chang KJ, Chung HJ, Yoo MC, Yang HJ, Kang JH et al (2012) Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes. Exp Mol Med 44:665–673CrossRefGoogle Scholar
  14. Koh JH, Lee ES, Hyun M, Kim HM, Choi YJ, Lee EY, Yaday D, Chung CH (2014) Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model. Int J Endocrinol 2014:397307CrossRefGoogle Scholar
  15. Kulakowski EC, Maturo J (1984) Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem Pharmacol 33:2835–2838CrossRefGoogle Scholar
  16. Luippold G, Bedenik J, Voigt A, Grempler R (2016) Short- and longterm glycemic control of streptozotocin-induced diabetic rats using different insulin preparations. PLoS One 11:e0156346CrossRefGoogle Scholar
  17. Mikami N, Hosokawa M, Miyashita K (2012) Dietary combination of fish oil and taurine decreases fat accumulation and ameliorates blood glucose levels in type 2 KK-Ay mice. J Food Sci 77:H114–H120CrossRefGoogle Scholar
  18. Murakami S, Fujita M, Nakamura M, Sakono M, Nishizono S, Sato M, Imaizumi K, Mori M, Fujuda N (2016) Taurine ameliorates cholesterol metabolism by stimulating bile acid production in high-cholesterol-fed rats. Clin Exp Pharmacol Physiol 43:372–378CrossRefGoogle Scholar
  19. Nishimura N, Umeda C, Oda H, Yokogoshi H (2002) The effect of taurine on plasma cholesterol concentration in genetic type 2 diabetic GK rats. J Nutr Sci Vitaminol 48:483–490CrossRefGoogle Scholar
  20. Owen MR, Doran E, Halestrap AP (2000) Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607–614CrossRefGoogle Scholar
  21. Pandya KG, Budhram R, Clark GJ, Lau-Cam CA (2015) Taurine can enhance the protective actions of metformin against diabetes-induced alterations adversely affecting renal function. Adv Exp Med Biol 803:227–250CrossRefGoogle Scholar
  22. Periello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB (1994) Acute anti-hyperglycemic mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43:920–928CrossRefGoogle Scholar
  23. Pournaghi P, Sadrkhanlou RA, Hasanzadeh S, Foroughi A (2012) An investigation on body weights, blood glucose levels and pituitary-gonadal axis hormones in diabetic and metformin-treated diabetic female rats. Vet Res Forum 3:79–84PubMedPubMedCentralGoogle Scholar
  24. Raabo E, Terkildsen TC (1960) On the enzymatic determination of blood glucose. Scand J Clin Invest 12:402–407CrossRefGoogle Scholar
  25. Rena G, Hardie DG, Pearso ER (2017) The mechanisms of action of metformin. Diabetologia 60:1577–1585CrossRefGoogle Scholar
  26. Ribeiro RA, Bonfleur ML, Amaral AG, Vanzela EC, Rocco SA, Boschero AC, Carneiro EM (2009) Taurine supplementation enhances nutrient-induced insulin secretion in pancreatic mice islets. Diabetes Metab Res Rev 25:370–379CrossRefGoogle Scholar
  27. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS (1998) The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 21:701–705CrossRefGoogle Scholar
  28. Saleh AA (2012) Effects of taurine and/or ginseng and their mixture on lipid profile and some parameters indicative of myocardial status in streptozotocin-diabetic rats. J Basic Appl Zool 65:267–273CrossRefGoogle Scholar
  29. Stowe NT, Cressman MD, Brouhard BH, Nally JV Jr, Vidt DG, Inman SR, Satoh S, Satodate R (1999) Lovastatin preserves renal function in experimental diabetes. Am J Med Sci 317:215–221CrossRefGoogle Scholar
  30. Tenner TE Jr, Zhang XJ, Lombardini JB (2003) Hypoglycemic effects of taurine in the alloxan-treated rabbit, a model for type 1 diabetes. Adv Exp Med Biol 526:97–104CrossRefGoogle Scholar
  31. Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, Stein E, Jones PH, Schaefer EJ (2011) Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol 107:387–392CrossRefGoogle Scholar
  32. Tobin BW, Welch-Holland KR, Marchello MJ (2000) Increased body fat in streptozotocin diabetic rats treated with intensive subcutaneous insulin therapy vs. islet transplantation. Can J Physiol Pharmacol 78:622–630CrossRefGoogle Scholar
  33. Tokunaga Y, Yoneda Y, Kuriyama K (1983) Streptozotocin-induced elevation of a pancreatic taurine content and suppressive effect of taurine on insulin secretion. Eur J Pharmacol 87:237–243CrossRefGoogle Scholar
  34. Tsuchiya Y, Kawamata K (2017) Effects of taurine on plasma glucose concentration and active glucose transport in the small intestine. Anim Sci J 88:1763–1767CrossRefGoogle Scholar
  35. Vergés B (2015) Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 58:886–899CrossRefGoogle Scholar
  36. Wang L, Zhang L, Yu Y, Wang Y, Niu N (2008) The protective effects of taurine against early renal injury in STZ-induced diabetic rats, correlated with inhibition of renal LOX-1-mediated ICAM-1 expression. Ren Fail 30:763–671CrossRefGoogle Scholar
  37. Yanagita T, Han S-Y, Hu Y, Nagao K, Kitajima H, Murakami S (2008) Taurine reduces the secretion of apolipoprotein B100 and lipids in HepG2 cells. Lipids Health Dis 7:38CrossRefGoogle Scholar
  38. Yokogoshi H, Mochizuki H, Nanami K, Hida Y, Miyachi F, Oda H (1999) Dietary taurine enhances cholesterol degradation and reduces serum and liver cholesterol concentrations in rats fed a high-cholesterol diet. J Nutr 129:1705–1712CrossRefGoogle Scholar
  39. Zhang M, Bi LF, Fang JH, Su XL, Da GL, Kuwamori T, Kagamimori S (2004) Beneficial effects of taurine on serum lipids in overweight or obese non-diabetic subjects. Amino Acids 26:267–271PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Kashyap Pandya
    • 1
  • Cesar A. Lau-Cam
    • 1
  1. 1.Department of Pharmaceutical Sciences, College of Pharmacy and Health ProfessionsSt. John’s UniversityJamaicaUSA

Personalised recommendations